Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
Stopped early · Phase 1
Conditions studied: Malignancies
In brief
The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.
Key facts
- Study ID
- NCT00329329
- Run by
- Agennix
- People needed
- 24
- Starts
- 2006-05-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2012-03-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University Medical Center — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.